Program Content


  • FAQs: HER2-Positive GI Cancers
    Targeted Therapies for HER2-Positive Gastrointestinal Cancers: Experts Answer Your Questions
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 12, 2023


cover img faculity

Geoffrey Ku, MD

Associate Attending Physician
Head, Esophagogastric Section, Gastrointestinal Oncology Service & member, Cellular Therapy Service
Department of Medicine

cover img faculity

Kanwal Raghav, MD

Associate Professor
Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Zev A. Wainberg, MD

Professor of Medicine and Surgery
Co-Director, GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Provided by

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.


Daiichi Sankyo, Inc.

Seagen Inc.